Roche Holding AG’s Avastin delayed progression of ovarian cancer and cut the rate of death in some women with the disease in two studies. They didn’t show that the $58,000-a-year therapy could improve survival.
Dennis Prestholdt credits the past three years of his life to Johnson & Johnson ’s Zytiga, the first prostate cancer pill to win U.S. marketing approval in a family of treatments that offer new ways to stymie the male hormones that fuel tumor growth.
Intermune Inc. , which won European approval Feb. 28 for Esbriet, will start selling the lung- disease drug in September in Germany and in other parts of Europe next year, Chief Executive Officer Dan Welch said.
A Roche Holding AG experimental drug called MetMab, used with another medicine, extended the lives of lung-cancer patients whose tumors had high levels of a protein known to trigger the disease and help it spread, a study found.
Vivus Inc. said its effort to win regulatory approval for weight-loss pill Qnexa may be helped by a study showing little risk of birth defects in children of women who took one of the medicine’s ingredients.
Optimer Pharmaceuticals Inc. ’s Dificid is on track to lead as many as five new antibiotics onto the market over the next three years as a surge in drug- resistant germs stokes the need for new medicines.
Exelixis Inc. ’s experimental pill reduced malignant growths in the bones of 86 percent of men with prostate cancer and cut the spread of tumor cells in one-fourth of women with ovarian cancer in a company study.